(NYSE: NVS) Novartis Ag's forecast annual revenue growth rate of 2.1% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.76%.
Novartis Ag's revenue in 2024 is $49,924,000,000.On average, 4 Wall Street analysts forecast NVS's revenue for 2024 to be $99,645,790,560,000, with the lowest NVS revenue forecast at $97,348,055,312,000, and the highest NVS revenue forecast at $102,233,431,961,200. On average, 4 Wall Street analysts forecast NVS's revenue for 2025 to be $105,447,621,030,800, with the lowest NVS revenue forecast at $102,760,950,856,000, and the highest NVS revenue forecast at $109,943,689,360,000.
In 2026, NVS is forecast to generate $107,840,853,120,000 in revenue, with the lowest revenue forecast at $104,836,221,292,000 and the highest revenue forecast at $112,318,190,577,200.